IPO Databook: Valion Bio (VBIO US) - Jul 2026

232 Views19 Jul 2026 10:13

SUMMARY

Valion Bio is a late-stage biopharmaceutical company advancing Entolimod for acute radiation syndrome and oncology, having recently pivoted and established Velocity Bioworks.
Valion Bio secured exclusive worldwide rights to Entolimod, a lead program with FDA Fast Track and Orphan Drug designations for ARS, supported by extensive trials.
The auditor's report raises substantial doubt about Valion Bio's ability to continue as a going concern, requiring significant additional funding for long-term operations.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream